Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 1,119,834 |
|
|||||
| News | - | ||||||
| Day High | 7.77 | Low High |
|||||
| Day Low | 7.25 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nkarta Inc | NKTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.04 | 0.53% | 7.53 | 15:26:57 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.63 | 7.25 | 7.77 | 7.53 | 7.49 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 13,257 | 1,119,834 | US$ 7.57 | US$ 8,481,092 | - | 1.28 - 16.24 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:08:21 | 10 | US$ 7.68 | USD |
Nkarta Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 369.02M | 49.07M | - | 0 | -117.5M | -2.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Nkarta News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NKTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.03 | 7.77 | 6.47 | 6.98 | 996,463 | 0.50 | 7.11% |
| 1 Month | 9.71 | 10.16 | 6.47 | 7.98 | 952,262 | -2.18 | -22.45% |
| 3 Months | 10.20 | 16.24 | 6.47 | 10.17 | 993,273 | -2.67 | -26.18% |
| 6 Months | 1.96 | 16.24 | 1.89 | 8.79 | 1,510,989 | 5.57 | 284.18% |
| 1 Year | 5.18 | 16.24 | 1.28 | 5.82 | 1,491,861 | 2.35 | 45.37% |
| 3 Years | 32.695 | 40.64 | 1.28 | 10.63 | 991,806 | -25.17 | -76.97% |
| 5 Years | 54.75 | 79.16 | 1.28 | 12.41 | 825,266 | -47.22 | -86.25% |
Nkarta Description
| Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment. |
